Abu-El-Rub E, Alzubi A, Almahasneh F, Khaswaneh R, Almazari R, Kasasbeh A
Mol Biol Rep. 2025; 52(1):212.
PMID: 39921807
PMC: 11807072.
DOI: 10.1007/s11033-025-10303-x.
Nian Q, Lin Y, Zeng J, Zhang Y, Liu R
Transl Oncol. 2024; 52():102237.
PMID: 39672002
PMC: 11700300.
DOI: 10.1016/j.tranon.2024.102237.
Saber S, Abdelhady R, Elhemely M, Elmorsy E, Hamad R, Abdel-Reheim M
Front Pharmacol. 2024; 15:1475998.
PMID: 39564119
PMC: 11573589.
DOI: 10.3389/fphar.2024.1475998.
Zmorzynski S, Kimicka-Szajwaj A, Szajwaj A, Czerwik-Marcinkowska J, Wojcierowski J
Genes (Basel). 2024; 15(1).
PMID: 38275618
PMC: 10815783.
DOI: 10.3390/genes15010137.
Mooradian M, Cleary J, Giobbie-Hurder A, Darville L, Parikh A, Buchbinder E
Cancer. 2023; 129(12):1904-1918.
PMID: 37042037
PMC: 10793106.
DOI: 10.1002/cncr.34730.
MicroRNA-570 targets the HSP chaperone network, increases proteotoxic stress and inhibits mammary tumor cell migration.
Okusha Y, Guerrero-Gimenez M, Lang B, Borges T, Stevenson M, Truman A
Sci Rep. 2022; 12(1):15582.
PMID: 36114410
PMC: 9481609.
DOI: 10.1038/s41598-022-19533-6.
Upregulation of TGF-β-induced HSP27 by HSP90 inhibitors in osteoblasts.
Kuroyanagi G, Tokuda H, Fujita K, Kawabata T, Sakai G, Kim W
BMC Musculoskelet Disord. 2022; 23(1):495.
PMID: 35619094
PMC: 9134601.
DOI: 10.1186/s12891-022-05419-1.
Studies on Preformulation and Formulation of JIN-001 Liquisolid Tablet with Enhanced Solubility.
Kim H, Kim C, Jo A, Kim J
Pharmaceuticals (Basel). 2022; 15(4).
PMID: 35455409
PMC: 9030333.
DOI: 10.3390/ph15040412.
Extracellular HSPs: The Potential Target for Human Disease Therapy.
Li D, Liang S, Wen J, Tang J, Deng S, Liu Y
Molecules. 2022; 27(7).
PMID: 35408755
PMC: 9000741.
DOI: 10.3390/molecules27072361.
A novel C-terminal heat shock protein 90 inhibitor that overcomes STAT3-Wnt-β-catenin signaling-mediated drug resistance and adverse effects.
Lee H, Min H, Yong Y, Ann J, Nguyen C, La M
Theranostics. 2022; 12(1):105-125.
PMID: 34987637
PMC: 8690924.
DOI: 10.7150/thno.63788.
AUY922 induces retinal toxicity through attenuating TRPM1.
Shen C, Hsieh C, Jiang K, Lin C, Chiang N, Li T
J Biomed Sci. 2021; 28(1):55.
PMID: 34301262
PMC: 8306347.
DOI: 10.1186/s12929-021-00751-5.
The dark-side of the outside: how extracellular heat shock proteins promote cancer.
Secli L, Fusella F, Avalle L, Brancaccio M
Cell Mol Life Sci. 2021; 78(9):4069-4083.
PMID: 33544155
PMC: 8164615.
DOI: 10.1007/s00018-021-03764-3.
Measuring Tumor Epichaperome Expression Using [I] PU-H71 Positron Emission Tomography as a Biomarker of Response for PU-H71 Plus Nab-Paclitaxel in HER2-Negative Metastatic Breast Cancer.
Jhaveri K, Dos Anjos C, Taldone T, Wang R, Comen E, Fornier M
JCO Precis Oncol. 2020; 4.
PMID: 33283132
PMC: 7713524.
DOI: 10.1200/PO.20.00273.
The one thousand and one chaperones of the NF-κB pathway.
Fusella F, Secli L, Cannata C, Brancaccio M
Cell Mol Life Sci. 2019; 77(12):2275-2288.
PMID: 31811308
PMC: 11104964.
DOI: 10.1007/s00018-019-03402-z.
Novel Hsp90 Inhibitor C086 Potently Inhibits Non-Small Cell Lung Cancer Cells As A Single Agent Or In Combination With Gefitinib.
Wang L, Fan Y, Mei H, Liu Y, Zhang L, Xu J
Cancer Manag Res. 2019; 11:8937-8945.
PMID: 31802936
PMC: 6801566.
DOI: 10.2147/CMAR.S215970.
Hsp90 middle domain phosphorylation initiates a complex conformational program to recruit the ATPase-stimulating cochaperone Aha1.
Xu W, Beebe K, Chavez J, Boysen M, Lu Y, Zuehlke A
Nat Commun. 2019; 10(1):2574.
PMID: 31189925
PMC: 6561935.
DOI: 10.1038/s41467-019-10463-y.
The Potential of Targeting P53 and HSP90 Overcoming Acquired MAPKi-Resistant Melanoma.
Hsieh C, Shen C
Curr Treat Options Oncol. 2019; 20(3):22.
PMID: 30778775
DOI: 10.1007/s11864-019-0622-9.
Development of a novel Hsp90 inhibitor NCT-50 as a potential anticancer agent for the treatment of non-small cell lung cancer.
Hyun S, Le H, Nguyen C, Yong Y, Boo H, Lee H
Sci Rep. 2018; 8(1):13924.
PMID: 30224681
PMC: 6141536.
DOI: 10.1038/s41598-018-32196-6.
Dual targeting of HSP70 does not induce the heat shock response and synergistically reduces cell viability in muscle invasive bladder cancer.
Prince T, Ackerman A, Cavanaugh A, Schreiter B, Juengst B, Andolino C
Oncotarget. 2018; 9(66):32702-32717.
PMID: 30220976
PMC: 6135696.
DOI: 10.18632/oncotarget.26021.
Triptolide, a HSP90 middle domain inhibitor, induces apoptosis in triple manner.
Zhang F, Ho D, Wong R
Oncotarget. 2018; 9(32):22301-22315.
PMID: 29854279
PMC: 5976465.
DOI: 10.18632/oncotarget.24737.
